Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Realty & pharma in limelight
Fri, 7 Nov 01:30 pm

Indian share markets continued to trade weak in the post-noon trading session. Majority of the sectoral indices are trading in the red with engineering and auto stocks being the biggest losers. However, realty and pharma are among the few stocks trading strong today.

BSE-Sensex is down 61 points and NSE-Nifty is trading 11 points down. BSE Mid Cap is trading 0.4% up while BSE Small Cap index is trading down marginally. The rupee is trading at 61.53 to the US dollar.

FMCG stocks are trading mixed with Colgate and Marico among the major gainers whereas Lakshmi Energy and Bata India are the biggest losers. As per a leading financial daily, Colgate has declared its results for the quarter ended September 2014. The company posted a 11% YoY topline growth on a 7% volume growth in toothpastes during the quarter. Its volume market share in the toothpaste category for the period January-September 2014 increased by 0.8% YoY to 56.7%. Even its operating margin expanded by 2.4% YoY to 18.6% backed by lower input costs and ad-spends (both as a proportion of sales). However at the net level, the margin expended by a mere 0.8% YoY on account of a steep 52% jump in depreciation and lower other income earned for the quarter. Colgate stock is currently trading up 2.96%.

Most of the domestic pharma companies are trading strong led by Cadial Healthcare and Glenmark Pharma. According to a leading financial daily, Dr Reddy's Laboratories (DRL) has won final approval from US Food and Drug Administration (USFDA) to make cheaper copies of Roche Holdings AG's anti viral drug Valcyte. Earlier Ranbaxy Laboratories lost out its tentative approval for the six-month exclusivity for the generic drug on account of quality issues at its manufacturing plants. Ranbaxy's domestic manufacturing plants have been banned by USFDA from exporting to the US. DRL stock is up 3% and Ranbaxy stock is up 0.7%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Realty & pharma in limelight". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.